Clinical trials update from the European Society of Cardiology Meeting 2011: ARISTOTLE, SMART-AV: QLV substudy, SHIFT: Echocardiography and quality of life substudies, European CRT Survey, and Basic Science Update

European Journal of Heart Failure

Volumn 13, Issue 12, 2011, Pages 1376-1380

  Cleland, John G F ^a   Coletta, Alison P ^a   Cullington, Damien ^a   Castiello, Teresa ^a   De Boer, Rudolf A ^b   Clark, Andrew L ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Heart failure; Randomized controlled trials

Indexed keywords

APIXABAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IVABRADINE; PLACEBO; WARFARIN;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL (TOPIC); DRUG DOSE TITRATION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EUROPE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HEART VENTRICLE FUNCTION; HUMAN; MEDICAL SOCIETY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PREVENTION STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; STROKE; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

CARDIAC RESYNCHRONIZATION THERAPY; CARDIOLOGY; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; EUROPE; HEART FAILURE; HUMANS; QUALITY OF LIFE; SOCIETIES, MEDICAL;

EID: 81855211006     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr149     Document Type: Article

References (31)

1. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-1912.
2. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo A, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon J-L, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
3. Cleland JGF, Coletta AP, Yassin A, Buga L, Torabi A, Clark AL. Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT Survey, German pre-SCD II registry, and MADIT-CRT. Eur J Heart Fail 2009;11:1214-1219.
4. Cleland JGF, Atkin SL. Thiazolidinediones, deadly sins, surrogates and elephants. Lancet 2007;370:1103-1104. (Pubitemid 47464564)
5. Cleland JGF, Witte KK, Steel S. Calcium supplements in people with osteoporosis. BMJ 2010;341:c3856.
6. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, Van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, Vahanian A, Camm J, De CR, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Tendera M, Auricchio A, Bax J, Bohm M, Corra U, della BP, Elliott PM, Follath F, Gheorghiade M, Hasin Y, Hernborg A, Jaarsma T, Komajda M, Kornowski R, Piepoli M, Prendergast B, Tavazzi L, Vachiery JL, Verheugt FW, Zamorano JL, Zannad F. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
7. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Messenger J, for the MIRACLE Study Group. Cardiac resynchronisation in chronic heart failure. N Engl J Med 2002;346: 1845-1853. (Pubitemid 34603028)
8. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L, for the Cardiac Resynchronisation-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. New Engl J Med 2005;352:1539-1549. (Pubitemid 40517094)
9. Lubitz SA, Leong-Sit P, Fine N, Kramer DB, Singh J, Ellinor PT. Effectiveness of cardiac resynchronisation therapy in mild congestive heart failure: systematic review and meta-analysis of randomized controlled trials. Eur J Heart Fail 2010; 10:360-366.
10. Cleland JGF, Freemantle N, Daubert J-C, Toff W, Leisch F, Tavazzi L. Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF Study. Heart 2008;94:278-283. (Pubitemid 351303415)
11. Van Veldhuisen DJ, Maas AH, Priori SG, Stolt P, van Gelder IC, Dickstein K, Swedberg K. Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. Eur J Heart Fail 2009;11: 1143-1151.
12. Cleland JG, Tavazzi L, Daubert J-C, Tageldien A, Freemantle N. Cardiac resynchronization therapy. are modern myths preventing appropriate use? J Am Coll Cardiol 2009;53:608-611.
13. Cleland JG, Freemantle N, Ghio S, Fruhwald F, Shankar A, Marijianowski M, Verboven Y, Tavazzi L. Predicting the long-term effects of cardiac resynchronisation therapy on mortality from baseline variables and the early response: a report from CARE-HF (Cardiac Resynchronisation in Heart Failure). J Am Coll Cardiol 2008;52:438-445. (Pubitemid 352040815)
14. Cleland JG, Coletta A, Buga L, Antony R, Pellicori P, Freemantle N, Clark AL. Clinical trials update from the American Heart Association Meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. Eur J Heart Fail 2011;13:460-465.
15. Ellenbogen KA, Gold MR, Meyer TE, Lozano IF, Mittal S, Waggoner AD, Lemke B, Singh JP, Spinale FG, van Eyk JE, Whitehill J, Weiner S, Bedi M, Rapkin J, Stein KM. Primary results from the SmartDelay determined AV optimization: a comparison to other delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography- guided and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation 2010;122: 2660-2668.
16. Gold MR, Birgersdotter-Green UM, Singh JP, Ellenbogen KA, Yu Y, Meyer TE, Seth M, Tchou PJ. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronisation therapy. Eur Heart J 2011;in press (doi:10.1093/eurheart/ehr329).
17. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, on behalf of the SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised controlled study. Lancet 2010;376:875-885.
18. Cleland JGF, Coletta AP, Torabi A, Ahmed D, Clark AL. Clinical trials update from the European Society of Cardiology Meeting 2010: SHIFT, PEARL-HF, STARheart, and HEBE-III. Eur J Heart Fail 2010;12:1261-1264.
19. Tardif J-C, O'Meara E, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L, Swedberg K, on behalf of the SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011;in press (doi:10.1093/eurheartj/ehr311).
20. Ekman I, Chassany O, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L, Swedberg K. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 2011;32:2395-2404.
21. Cullington D, Goode KM, Cleland JG, Clark AL. Rate criteria provide limited application for ivabradine in chronic heart failure. Heart 2011;in press [Epub ahead of print].
22. Dobre D, van Jaarsveld CH, DeJongste MJ, Haaijer-Ruskamp FM, Ranchor AV. The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2007;16: 152-159. (Pubitemid 46291167)
23. Cleland JGF, Coletta AP, Castiello T, Clark AL. Clinical trials update from the European Society of Cardiology Heart Failure meeting 2011: TEHAF, WHICH, CARVIVA and atrial fibrillation in GISSI-HF, and EMPHASIS-HF. Eur J Heart Fail 2011;13:1147-1151.
24. Volterrani M, Cice G, Caminiti G, Vitale C, D'Isa S, Perrone-Filardi P, Acquistapace F, Marazzi G, Fini M, Rosano GM. Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). Int J Cardiol 2011;151:218-224.
25. Cleland JGF, Coletta AP, Freemantle N, Clark AL. Clinical trials update from the American Heart Association Meeting 2009: HEAAL, FAIR-HF, J-CHF, HeartMate II, and PACE. Eur J Heart Fail 2010;12:197-201.
26. Dickstein K, Bogale N, Priori S, Auricchio A, Cleland JGF, Gitt A, Limbourg T, Linde C, Van Veldhuisen DJ, Brugada J, on behalf of the Scientific Committee and National Coordinators. The European Cardiac Resynchronization Therapy Survey. Eur Heart J 2009;30:2450-2460.
27. McNamara DM, London B. GWAS applied to heart failure: bigger will be better . . . eventually. Circ Cardiovasc Genet 2010;3:226-228.
28. Waldmüller S, Erdmann J, Binner P, Gelbrich G, Pankuweit S, Geier C, Timmermann B, Haremza J, Perrot A, Scheer S, Wachter R, Schulze-Waltrup N, Dermintzoglou A, Schönberger J, Zeh W, Jurmann B, Brodherr T, Börgel J, Farr M, Milting H, Blankenfeldt W, Reinhardt R, Ozcelik C, Osterziel KJ, Loeffler M, Maisch B, Regitz-Zagrosek V, Schunkert H, Scheffold T, on behalf of the German Competence Network Heart Failure. Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German Competence Network Heart Failure. Eur J Heart Fail 2011;in press [Epub ahead of print].
29. Knöll R, Iaccarino G, Tarone G, Hilfiker-Kleiner D, Bauersachs J, Leite-Moreira AF, Sugden PH, Balligand JL. Towards a re-definition of 'cardiac hypertrophy' through a rational characterization of left ventricular phenotypes: a position paper of the Working Group 'Myocardial Function' of the ESC. Eur J Heart Fail 2011;13: 811-819.
30. van Berlo JH, de Voogt WG, van der Kooi AJ, van Tintelen JP, Bonne G, Yaou RB, Duboc D, Rossenbacker T, Heidbüchel H, de Visser M, Crijns HJ, Pinto YM.Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death?J Mol Med (Berl)2005;83:79-83. (Pubitemid 40169500)
31. Moller DV, Pham TT, Gustafsson F, Hedley P, Ersboll MK, Bundgaard H, Andersen CB, Torp-Pedersen C, Kober L, Christiansen M. The role of lamin A/C mutations in Danish patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail 2009;11:1031-1035.